<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657120</url>
  </required_header>
  <id_info>
    <org_study_id>HYDRA (29BRC20.0087)</org_study_id>
    <nct_id>NCT04657120</nct_id>
  </id_info>
  <brief_title>Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy</brief_title>
  <acronym>HYDRA</acronym>
  <official_title>Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy : HYDRA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to prospectively validate the safety and efficiency of management&#xD;
      according to the YEARS algorithm to safely rule out clinically suspected PE in patients with&#xD;
      active malignancy to be compared with 'standard' management by computed tomography pulmonary&#xD;
      angiography (CTPA) alone in a randomized study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, the YEARS-algorithm was demonstrated to be a safe and efficient diagnostic strategy&#xD;
      for patients with clinically suspected pulmonary embolism (PE). It is recognized that&#xD;
      diagnostic algorithms for pulmonary embolism (PE) may not be as effective and safe in&#xD;
      patients with malignancy, due to the low specificity of D-dimer test in that setting. A&#xD;
      diagnostic algorithm that could safely rule out PE in patients with malignancy without&#xD;
      performing computed tomography pulmonary angiography (CTPA) could nonetheless improve patient&#xD;
      care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent PE</measure>
    <time_frame>3 months</time_frame>
    <description>Recurrent PE will be observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Deep vein thrombosis (DVT)</measure>
    <time_frame>3 months</time_frame>
    <description>Number of DVT will be observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>3 months</time_frame>
    <description>The mortality will be observed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CTPA</measure>
    <time_frame>3 months</time_frame>
    <description>Number of performed CTPA will be observed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>YEARS algorithm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this arm will be evaluated according to the YEARS algorithm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTPA as single test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this arm will undergo a contrast enhanced CTPA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>YEARS</intervention_name>
    <description>Patients randomized to the YEARS algorithm will be evaluated according to the YEARS algorithm consisting of three items of the original Wells rule (clinical signs of DVT, hemoptysis and 'PE most likely diagnosis') and a D-dimer test. In patients without any of the three items and a D-dimer level &lt;1.0 μg/mL, and in patients with ≥1 items and a D-dimer level &lt;0.5 μg/mL a PE is excluded without CTPA. In the other patients a standard contrast enhanced CTPA will be performed according to local practice. PE is defined as at least one filling defect in the pulmonary artery tree on CTPA.</description>
    <arm_group_label>YEARS algorithm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CTPA</intervention_name>
    <description>Patients randomized to the CTPA management group will undergo a contrast enhanced CTPA to rule out PE according to standard local practice.</description>
    <arm_group_label>CTPA as single test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to be eligible to participate in this study, a subject must meet all of the&#xD;
        following criteria:&#xD;
&#xD;
          -  Clinically suspected PE as judged by the treating clinician&#xD;
&#xD;
          -  Any type of active malignancy (other than basal-cell or squamous-cell carcinoma of the&#xD;
             skin), defined as diagnosis within six months before the study inclusion (as confirmed&#xD;
             histologically or high suspicion as judged by the clinician), receiving treatment for&#xD;
             malignancy at time of inclusion or during 6 months prior to randomization, including&#xD;
             recurrent or local metastatic malignancy&#xD;
&#xD;
          -  Outpatients and hospitalized patients&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Signed and dated informed consent, available for start of the trial procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A potential subject who meets any of the following criteria will be excluded from&#xD;
        participation in this study:&#xD;
&#xD;
          -  Medical or psychological condition that would not permit completion of the study or&#xD;
             signing of informed consent, including life expectancy less than 3 months, or&#xD;
             unwillingness to sign informed consent&#xD;
&#xD;
          -  Treatment with full-dose therapeutically dosed anticoagulation that was initiated 24&#xD;
             hours or more prior to eligibility assessment&#xD;
&#xD;
          -  Contraindication to CTPA&#xD;
&#xD;
               -  contrast allergy&#xD;
&#xD;
        Hemodynamic instability at presentation (as a consequence of concurrent acute PE or&#xD;
        otherwise), indicated by at least one of the following:&#xD;
&#xD;
          -  systolic blood pressure (SBP) &lt; 100 mm Hg, or heart rate &gt;120 beats per minute or SBP&#xD;
             drop by &gt; 40 mm Hg, for &gt; 15 min&#xD;
&#xD;
          -  need for catecholamines to maintain adequate organ perfusion and a systolic blood&#xD;
             pressure of &gt; 100 mmHg&#xD;
&#xD;
          -  Need for cardiopulmonary resuscitation&#xD;
&#xD;
          -  Inability to follow-up&#xD;
&#xD;
          -  Life expectancy less than 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis COUTURAUD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Brest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francis COUTURAUD, Pr</last_name>
    <phone>02 98 34 73 47</phone>
    <phone_ext>+33</phone_ext>
    <email>francis.couturaud@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre-Marie ROY, Pr</last_name>
      <phone>02 41 35 66 50</phone>
      <phone_ext>+33</phone_ext>
      <email>PMRoy@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Francis COUTURAUD, Pr</last_name>
      <phone>02 98 34 73 47</phone>
      <phone_ext>+33</phone_ext>
      <email>francis.couturaud@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jeannot SCHMIDT, Pr</last_name>
      <phone>04 73 75 19 99</phone>
      <phone_ext>+33</phone_ext>
      <email>jschmidt@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Mourier - APHP</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Isabelle MAHE, Pr</last_name>
      <phone>01 47 60 64 90</phone>
      <phone_ext>+33</phone_ext>
      <email>isabelle.mahe@lmr.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Guy MEYER, Pr</last_name>
      <phone>01 65 09 34 61</phone>
      <phone_ext>+33</phone_ext>
      <email>guy.meyer@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent BERTOLETTI, Dr</last_name>
      <phone>04 77 12 77 70</phone>
      <phone_ext>+33</phone_ext>
      <email>laurent.bertoletti@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available after the publication of result and ending fifteen years following the last visit of the last patient</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

